Convergent Therapeutics is a pharmaceutical company based in Cambridge, Massachusetts, that specializes in creating radiopharmaceutical therapies for prostate cancer. The company was established by Neil H. Bander and Philip Wayne Kantoff. Convergent Therapeutics is focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers using proprietary dual-targeted radionuclide therapy developed by Dr. Neil Bander. The company's lead product, CONV 01-a, is a monoclonal antibody conjugated with 225Ac, a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA).

Tags

Urogenital Diseases

Neoplasms

Therapeutic radiopharmaceuticals

Radiolabeled antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Radiolabeled antibody	2
Therapeutic radiopharmaceuticals	2

Top 5 Target	Count

PSMA(Prostate-specific membrane antigen)	2

Drugs associated with Convergent Therapeutics, Inc.

Actinium 225-J591

Target

PSMA

Mechanism

PSMA inhibitors

Active Org.

Merck Sharp & Dohme Corp. [+1]

Originator Org.

Convergent Therapeutics, Inc.

Active Indication

PSMA-Positive Castration-Resistant Prostatic Cancer [+1]

Inactive Indication

Castration-sensitive prostate cancer [+1]

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

In-111 rosopatamab tetraxetan

Target

PSMA

Mechanism

PSMA modulators

Active Org.

Convergent Therapeutics, Inc.

Originator Org.

Convergent Therapeutics, Inc.

Active Indication

PSMA-Positive Castration-Resistant Prostatic Cancer

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Convergent Therapeutics, Inc.

NCT06549465

/ RecruitingPhase 2

A Phase 2, Open-label Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer

This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to characterize the biodistribution of the radioantibody to target organs and prostate cancer lesions. Participants then will be enrolled into either Part 2 (Dose Optimization) or Part 3 (Dose Escalation and Expansion) depending on their prior treatment history. Participants qualifying for Part 2 will be randomized to receive Ac-225 rosopatamab tetraxetan in a single fractionated cycle (dose administration on Day 1 and Day 15) at either 45 or 60 kBq/Kg. Participants qualifying for Part 3 must have received prior Lu-177-PSMA-radioligand therapy and will receive Ac-225 rosopatamab tetraxetan in a single fractionated cycle at 45, 55, or 60 kBq/Kg. Dose limiting toxicities (DLTs) will be monitored in Part 3 to determine the recommended phase 2 dose (RP2D), and the study may enroll additional participants to be treated with the RP2D dose level. Participants enrolled into any part will attend study visits which will include blood samples, electrocardiogram (ECG), radiographic imaging, and physical examinations along with other assessments.

Start Date06 Aug 2024

Sponsor / Collaborator

Convergent Therapeutics, Inc.

NCT05567770

/ WithdrawnPhase 1IIT

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

The purpose of this study is to evaluate the safety of combining Actinium- J591 with radiation therapy or with androgen deprivation therapy.

Start Date01 Dec 2023

Sponsor / Collaborator

Weill Medical College of Cornell University

[+1]

100 Clinical Results associated with Convergent Therapeutics, Inc.

0 Patents (Medical) associated with Convergent Therapeutics, Inc.

Literatures (Medical) associated with Convergent Therapeutics, Inc.

21 Apr 2025·Cancer Research

Abstract 980: Deaths from cardiovascular disease in rural and African American men with prostate cancer

Author: Munro, Heather M. ; Shrubsole, Martha J. ; Kantoff, Philip W. ; Stopsack, Konrad H. ; Bress, Adam ; Himbert, Caroline ; Mukamal, Kenneth J.

AbstractBackground:Cardiovascular disease (CVD) is a major cause of morbidity and mortality among men diagnosed prostate cancer. Different CVD risk factor profiles and disparities in healthcare access may place a higher burden on Black men and those living in rural areas diagnosed with prostate cancer.Methods:This cohort study aimed to evaluate differences in CVD deaths by rurality and race among men with prostate cancer. The Southern Community Cohort Study (SCCS) is a prospective cohort, which enrolled 34, 313 racially diverse, predominantly low-income men aged 40-79 in twelve southeastern states of the United States. Between 2002 and 2021, 1, 544 men with prostate cancer were free of prevalent CVD (i.e., coronary heart disease and stroke). Prostate cancer cases, vital status, and causes of death were identified through linkages to state cancer registries and the National Death Index as of December 31, 2022. Residence at enrollment was classified into rural and urban using community area codes. Lifetime risk for CVD death from Aalen-Johansen estimators and cause-specific hazard ratios (HRs) were computed.Results:356 participants (23%) were classified as rural and 1, 174 (76%) self-identified as African American. Over 21 years of follow-up (median 8 years), 618 deaths occurred, of which 149 (24%) were from CVD. The lifetime risk of CVD death was similar comparing men with prostate cancer living in urban and rural areas at about 20%. After adjusting for sociodemographics, cancer, and CVD risk factors, the hazard ratio (HR) for rurality and CVD death was 0.95 (95% confidence interval (CI): 0.66, 1.40). African American men had a higher lifetime risk of CVD death (21%, 95% (CI): 16, 28) than White men with prostate cancer (16%, 95% CI: 11, 24). The cause-specific HR for CVD deaths was 1.36 (95% CI: 0.91, 2.04) in African American men compared to White men. African American men tended to be diagnosed with prostate cancer at a younger age (age adjusted HR: 1.68; 95% CI: 1, 12, 2.52). The association was attenuated upon adjustment for social determinants of health reflected in community health center enrollment (HR: 1.02; 95% CI: 0.66, 1.59) and was essentially unchanged after further adjustments (HR: 0.99, 95% CI: 0.63, 1.57). African American men with CVD risk factors at prostate cancer diagnosis (hypertension, diabetes, hypercholesteremia), lower education level, or no insurance or Medicaid/Medicare coverage were at the highest risk for CVD death.Conclusions:African American men with prostate cancer face a higher age-adjusted risk of death from CVD than White men with prostate cancer. This association could mainly be explained by racial differences in social determinants of health reflected in community health center enrollment. Integrating sociodemographic characteristics into treatment planning and prioritizing CVD prevention and management along prostate cancer care may reduce CVD mortality among men with prostate cancer.Citation Format:Caroline Himbert, Heather M. Munro, Adam Bress, Philip W. Kantoff, Kenneth J. Mukamal, Martha J. Shrubsole, Konrad H. Stopsack. Deaths from cardiovascular disease in rural and African American men with prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 980.

01 Feb 2025·Cancer Research

Abstract A013: Clonal hematopoiesis as biomarker for 10-year risk of coronary heart disease in men with prostate cancer

Author: Stopsack, Konrad H ; Kantoff, Philip W ; Ma, Yuan ; Himbert, Caroline ; Bolton, Kelly L ; Mukamal, Kenneth J ; Chan, Irenaeus C. C. ; Mucci, Lorelei A

AbstractBackground: Men with prostate cancer have a high risk for cardiovascular disease (CVD), including coronary heart and cerebrovascular disease, following cancer diagnosis. Clonal hematopoiesis (CH) is associated with coronary heart disease (CHD) in the general population. We hypothesized that a higher burden of CH among men with non-metastatic prostate cancer is associated with an increased risk of CHD. Methods: This is a nested case-cohort study among men diagnosed with non-metastatic prostate cancer and free of CVD at cancer diagnosis within the prospective Health Professionals Follow-up Study. Men had to be free from prostate cancer and CVD at blood draw and at cancer diagnosis to be included. Men diagnosed with prostate cancer were followed for incident CHD events, defined as fatal and non-fatal myocardial infarction, coronary artery bypass graft surgery, and percutaneous coronary intervention infarction, over up to 10 years after cancer diagnosis. DNA was sequenced for putative CH driver mutations in the 9 most common CH-defining genes with a custom targeted panel (VariantPlex, Invitae, Inc.) at ultra-high depth (mean, 19,664X). CH variant calling used a novel ensemble calling approach, ArCH, validated with in-silico tumor dilutions and blinded technical replicates, which had high accuracy for variant allele frequency (VAFs) as low as 0.1%. Hazard ratios (HRs) with 95% confidence intervals (95% CI) were computed using proportional hazard regression models with Prentice case-cohort weights. Results: In a sample of 562 men with prostate cancer and free from CVD at cancer diagnosis, men had a median age at cancer diagnosis of 70 years and 48% were never smokers. 95% were diagnosed with stage I and II, and 70% had a Gleason score of ≤3+4. The median time between blood draw and cancer diagnosis was 7 years (interquartile range (IQR): 3, 12). There were 116 events over 10 years of follow-up after cancer diagnosis. 59% of men had no CH or very small clones (VAF ≤0.5%), 25% had VAFs 0.5-2%, 12% had VAFs 2-10%, and 3% had VAFs ≥10%. 61% of men had variants in epigenetic modifier genes (DNMT3A, TET2, ASXL1), and 3% had variants in DNA repair genes (PPM1D, TP53, CHEK2). CH ≥10% VAF was associated with an increased risk of CHD events following cancer diagnosis compared to no CH or very small clones after adjusting for age at blood draw and at cancer diagnosis (VAF ≤0.5%) (HR 2.94, 95% CI 1.04-8.33). After further adjustment for smoking status at blood draw the association was essentially unchanged (HR 2.90, 95% CI 1.02-8.23). The association between CH and CHD risk tended to become stronger with increasing VAFs compared to VAFs ≤0.5% (VAF 0.5-2%: HR 0.92, 95% CI 0.46-1.82; VAF 2-10%: HR 1.20, 95% CI 0.57-2.52). Results for epigenetic modifiers and DNA repair genes were not individually statistically significant. Conclusions: Results from this prospective cohort suggest that a higher burden of CH is associated with CHD and may be a potential biomarker for CHD risk among men with prostate cancer.Citation Format: Caroline Himbert, Irenaeus C. C. Chan, Yuan Ma, Kenneth J Mukamal, Lorelei A Mucci, Philip W Kantoff, Kelly L Bolton, Konrad H Stopsack. Clonal hematopoiesis as biomarker for 10-year risk of coronary heart disease in men with prostate cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer; 2025 Feb 1-4; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2025;85(3 Suppl):Abstract nr A013.

06 Jan 2025·Clinical Cancer Research

Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer

Article

Author: Stopsack, Konrad H. ; Pomerantz, Mark M. ; Freeman, Dory A. ; Abida, Wassim ; Offit, Kenneth ; Conry, Michael ; Berchuck, Jacob E. ; Morris, Michael J. ; Vijai, Joseph ; Penney, Kathryn L. ; Mandelker, Diana ; Lee, Gwo-Shu M. ; Vasselman, Samantha E. ; Solit, David B. ; Kemel, Yelena ; Mucci, Lorelei A. ; Kantoff, Philip W.

AbstractPurpose:Deleterious germline variants in certain DNA repair genes are risk factors for developing aggressive prostate cancer. The objective was to quantify their prognostic impact after prostate cancer diagnosis.Experimental Design:Men with prostate cancer, predominantly of European ancestry, were included from four cohorts with long-term follow-up. Pathogenic or likely pathogenic germline variants in 26 DNA repair genes were assessed in relation to metastasis-free survival in high-risk localized prostate cancer and to overall survival in metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC).Results:Among 3,525 patients initially diagnosed with nonmetastatic prostate cancer, 2,594 had high-risk localized prostate cancer, 429 had mCSPC, and 502 had mCRPC at inclusion. BRCA2 variant carriers did not have worse metastasis-free survival in high-risk localized prostate cancer [hazard ratio (HR), 1.01; 95% confidence interval (CI), 0.69–1.46] or overall survival in mCSPC (HR, 0.46; 95% CI, 0.14–1.45) or mCRPC (HR, 0.60; 95% CI, 0.31–1.17) compared with noncarriers of DNA repair variants. Among 868 additional patients with de novo metastatic (M1) prostate cancer, BRCA2 variant carriers tended to have worse overall survival (HR, 1.59; 95% CI, 1.01–2.51). BRCA2 prognostic associations were not explained by radiation, PARP inhibitor, or platinum therapy. Results for other genes were limited in precision because variants were less common.Conclusions:Among patients with high-risk or metastatic prostate cancer who were initially diagnosed with and treated for nonmetastatic tumors, germline DNA repair variants in BRCA2 do not confer a substantially worse prognosis.

News (Medical) associated with Convergent Therapeutics, Inc.

02 Apr 2025

·www.prnewswire.com

Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies

COPENHAGEN, Denmark, April 2, 2025 /PRNewswire/ -- Novo Holdings today announced its financial results for 2024.* Record returns from the Investment Portfolio and growth of the Novo Group companies drive Total Income and Investment Returns to DKK 60 billion (€8.0 billion) for 2024, up from DKK 31 billion (€4.2 billion) in 2023. The Investment Portfolio generated a return of 18.0%, compared with 9.4% in 2023. Including Special Investments,** the Total Investment Return for 2024 is 19.2%. Continue Reading Total Income and Investment Returns of DKK 60 billion consist of Income from dividends and the share repurchase programmes of the Novo Group companies (Novo Nordisk A/S and Novonesis A/S), totalling DKK 23 billion (€3.1 billion), and Returns from the Investment Portfolio generating an income of DKK 37 billion (€4.9 billion). The 5- and 10-year trailing returns of the Investment Portfolio are 10% for both horizons. Novo Holdings closed 2024 with Total Assets under Management of DKK 1,060 billion (€142 billion), down from 1,114 billion (€149 billion) in 2023, driven by a decline in the market value of Novo Nordisk. Kasim Kutay, CEO of Novo Holdings, said: "2024 was a very strong year for Novo Holdings, with our Investment Portfolio delivering its best ever performance and the Novo Group companies contributing significantly to our Total Income and Returns of DKK 60 billion (€8.0 billion). These results enable us to continue delivering on our purpose of improving people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation." Strong year for both Life Science and Capital Investments The Novo Holdings Investment Portfolio comprises Life Science Investments (Principal Investments, Growth Investments, Venture Investments, Seed Investments, Asia Investments and Planetary Health Investments), making up 59% of the total portfolio, and Capital Investments, making up the remaining 41% of the portfolio. The Capital Investments team provides global exposure beyond the life science sectors and, in alignment with the Novo Holdings Strategy 2030, is actively expanding and diversifying the total portfolio. The team focuses on public equity, fixed income, private equity and venture capital (non-life sciences), real assets, and credit. Further, Capital Investments enhances Novo Holdings' focus on the green transition by investing in the scaling of green infrastructure and renewable energy. In 2024, Capital Investments closed the year with DKK 95 billion (€13 billion) of Investment Assets and generated profits of DKK 13 billion (€1.7 billion). In Life Science Investments, the investment activities are focused on addressing human health and, increasingly, on the health of the planet via Novo Holdings' Planetary Health Investments platform. In 2024, Life Science Investments closed the year with DKK 134 billion (€18 billion) of Investment Assets and generated profits of DKK 24 billion (€3.2 billion). The Life Science Investments teams invested in a range of biotechnologies to advance new treatments for conditions such as cancer, cardiometabolic diseases, and neurodegenerative disorders, among other areas in which innovative therapies are crucial for improving patient outcomes. In 2024, Novo Holdings deployed DKK 34 billion (€4.6 billion) into life sciences. In total, 43 new companies were welcomed to the Investment Portfolio in 2024, and multiple follow-on investments were made. By year-end, Novo Holdings had exited 27 companies, and the Investment Portfolio comprised 181 companies. Landmark acquisition of Catalent With the $16.5 billion (DKK 118 billion) acquisition of Catalent, a global CDMO (Contract Development and Manufacturing Organisation), Novo Holdings' buyout platform, Principal Investments, led the largest healthcare buyout globally in 2024. Each year, Catalent supplies nearly 70 billion doses of more than 7,000 products and assembles over 320,000 clinical supply patient kits across 1,200 different protocols. Catalent has 1,500 active development programmes supported by more than 2,500 scientists and technicians and has supported nearly 50% of the FDA new drug approvals in the last 10 years, demonstrating the strength of its industry-leading capabilities. Christoffer Søderberg, Managing Partner, Principal Investments, said: "We are delighted to welcome Catalent to our portfolio. The pharma services sector is core to our investment strategy and aligns with our focus on fostering innovation and sustainable value creation across the life sciences ecosystem. Through our engaged ownership model we will leverage our extensive network and deep sector expertise to support Catalent's continued development, enabling the Company to expand its market leadership and deliver even greater value to its customers." In 2024, Novo Holdings embarked on the execution of its Strategy 2030, which encompasses operational scaling of our investment platforms and the acceleration of Planetary Health Investments to advance the green transition of society. "2024 was a successful year for Novo Holdings, not only in terms of financial performance, but also in strengthening our organisation with the addition of talented new colleagues. Their expertise will be instrumental as we advance the execution of Strategy 2030, with the continued scaling of our investment activities on our various platforms across both Capital Investments and Life Science Investments," said Kasim Kutay. "In 2025, we will build on this momentum, with a particular focus on Asia as we establish an office in India." *This performance report is an unaudited version of the 2024 performance of Novo Holdings. The audited version of the 2024 Annual Report of Novo Holdings is expected to be released in May 2025, since this is dependent on the release of the consolidated financial statements of the Novo Nordisk Foundation, expected to be released later than in previous years due to the merger of Chr. Hansen and Novozymes. **The Investment Portfolio excludes Special Investments, which comprise impact investments and assets held for Novo Nordisk Foundation strategic purposes. Total Investment Return including all assets is 19.2%. 2024 highlightsThe Novo Group Companies, Novo Nordisk A/S and Novonesis A/S delivered strong annual results. Novo Nordisk's sales increased by 25% in DKK and by 26% at constant exchange rates, and Novonesis reported 8% organic sales growth in 2024.The Capital Investments Portfolio generated a profit of DKK 13 billion (€1.7 billion), compared with DKK 7.6 billion (€1.0 billion) in 2023. Capital Investments' overall public investments portfolio had a strong performance in 2024 and delivered high absolute returns and outperformed its benchmark. The public equity portfolio delivered returns significantly above long-term average returns, but below the benchmark for the year. The private portfolio had a solid year, with performance improving after a difficult 2023. The overall performance was underpinned by declining interest rates and growth in underlying business fundamentals. Notable investments in 2024 include a DKK 1.1 billion (€150 million) follow-on investment in EuroClear, a global provider of financial market infrastructure, and a DKK 485 million (€65 million) renewable energy investment in Germany through a partnership with European Energy. Life Sciences – Principal Investments completed two new investments in 2024, deploying an aggregate amount of DKK 22.2 billion ($3.1 billion). One was the DKK 118 billion ($16.5 billion) acquisition of the US-listed global CDMO, Catalent. In connection with the Catalent transaction, Novo Holdings sold three of Catalent's nearly 50 global sites to Novo Nordisk for approximately DKK 79 billion ($11 billion). The second transaction was the investment in Single Use Support, a leading bioprocessing company and the first buyout for Novo Holdings in the strategically important DACH region. Principal Investments realised total proceeds of DKK 6.1 billion ($0.9 billion), mainly from full or partial divestments of public shareholdings, including the circa 17% shareholding in SYNLAB, which was sold to Cinven. Proceeds were also generated by partial monetisations in the private portfolio, including through recapitalisations in a number of portfolio companies. Life Sciences – Growth Investments had an active 2024, characterised by a significant acceleration of its investment activities, deploying DKK 1 billion ($0.2 billion). The team made three new investments, including leading a DKK 537 million ($75 million) financing round for Cleveland Diagnostics, a leading cancer diagnostics company; a DKK 430 million (£60 million) investment in Oxford Nanopore Technologies, a sequencing company at the forefront of nanopore-based molecular sensing technology; and a DKK 358 million ($50 million) investment in the Series F extension equity financing round for Route 92, a neurovascular intervention company. Additionally, the team led a Series E financing round, raising over DKK 430 million ($60 million) for Quanta Dialysis Technologies, an existing Novo Holdings portfolio company focused on making kidney care more accessible. Life Sciences – Venture Investments had one of its most active years, deploying a record DKK 4.9 billion ($0.7 billion), including DKK 3.2 billion ($0.4 billion) committed to 20 new investments. New portfolio companies include Obsidian Therapeutics, AvenCell Therapeutics, Kivu Biosciences, SiteOne Therapeutics, Convergent Therapeutics, Crystally, Arrivent Biopharma, Reunion Neurosciences, Myricx Bio, Asceneuron, Zenas Biopharma and Magenta Medical. Venture Investments exited 12 investments and realised total proceeds of DKK 3.7 billion ($0.5 billion) from the sales of publicly traded stock as well as from the divestments of several of its portfolio companies. Life Sciences – Seed Investments also had an active 2024, raising DKK 3.9 billion (€523 million) for its portfolio from international investors and deploying DKK 683 million (€92 million) in total. It also saw the launch of a Seed Investments sub-team, Novo Holdings Quantum Investments, committing DKK 1.4 billion (€188m) to invest in companies focused on disruptive technologies at the intersection of quantum technologies and the life sciences. Notable transactions in 2024 include closing of the DKK 1.0 billion ($135 million) Series B financing round for Adcendo and raising DKK 597 million ($80 million) for Antag Therapeutics' Series B financing. Seed Investments also closed a DKK 223 million (€30 million) Series A financing for Asgard Therapeutics and launched Orbis medicines, following a DKK 194 million (€26 million) seed financing and initiating its DKK 671 million (€90 million) Series A financing.Seed Investments continued to support the REPAIR Impact Fund for AMR (antimicrobial resistance) in 2024. Highlights from its portfolio include LimmaTech Biologics entering a strategic partnership with Valneva to accelerate the development of the LimmaTech-developed Tetravalent Shigella Bioconjugate Vaccine (S4V2). Paratek Pharmaceuticals announced strong efficacy data for NUZYRA® against anthrax. Life Sciences – Asia Investments, experienced a year of significant expansion, with several new investments and the decision to open our third Asia office in Mumbai, India, in 2025. Asia Investments deployed DKK 768 million ($107 million) in 2024. Notable transactions in 2024 include follow-on investments in Manipal Hospitals, a leading private hospital chain in India, and a pre-IPO investment in Medi Assist, a top-tier health benefits administrator serving patients across India. Asia Investments also invested in AgNext, an agricultural and food technology company, developing AI-based solutions for more sustainable agriculture. The transaction marked Novo Holdings' first investment in the planetary health sector in Asia. Additionally, Asia Investments participated in Qure.ai's Series D financing round as an existing investor. Life Sciences – Planetary Health Investments deployed DKK 2.6 billion (€348 million) in 2024. Notable transactions in 2024 include a DKK 1.1 billion (€150 million) co-investment in CIRCTEC, a company focused on end-of-life tyre recycling and an investment in Sejet Plant Breeding, a Danish company specialising in the development of new and improved crop varieties. Planetary Health Investments also closed a buyout of Norwegian aquaculture health company, Stingray Marine Solutions. Return on the Investment Portfolio The following table shows the 5- and 10-year returns for Life Science Investments, Capital Investments and the Total Investment Portfolio.*** The results for 2023 are included for comparison along with the long-term returns. Photo: ***The Investment Portfolio excludes Special Investments, which comprise impact investments and assets held for Novo Nordisk Foundation strategic purposes. Total Investment Return including all assets is 19.2%. Income and Investment Returns (in DKK (EUR) billion): Photo: As a holding and investment company, Novo Holdings invests to generate long-term returns. The Total Value of the Holding and Assets under Management was DKK 1,060 billion (€142 billion) at the end of 2024. Assets under Management (in DKK (EUR) billion): Photo: Notes: Income from the Novo Group includes dividends received from Novo Nordisk A/S and Novonesis A/S, in addition to income related to the sale of shares in Novo Group companies. Total Assets under Management (at market value) include Novo Group companies with A and B shares of the companies valued using the quoted B-price at close on 31 December of the respective year. Income and Investment Returns as well as Total Assets under Management include the Novo Nordisk Foundation's share of returns and assets. About the performance overview of the Investment Portfolio All returns are calculated in DKK and reflect total returns excluding internal costs. The returns on Life Science Investments are calculated as Internal Rate of Return (IRR) based on the book value at the end of the measurement period and cash flows within the measurement period, compared with the book value at the beginning of the measurement period. Capital Investments' returns and Investment Portfolio returns are based on Time Weighted Returns (TWR). Read the Novo Holdings Performance Report 2024 here. About Novo Holdings A/S Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2024, Novo Holdings had total assets of €142 billion. Further information: About the Novo Nordisk Foundation Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. The Foundation's mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support the green transition of society. Further information: SOURCE Novo Holdings WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionVaccineIPO

10 Feb 2025

·www.prnewswire.com

Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025

- Phase I Follow-Up Data Showed an Overall Survival of 29.8 Months with the Addition of CONV01-α to 177Lu-PSMA-I&T in Advanced Prostate Cancer CAMBRIDGE, Mass., Feb. 10, 2025 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced clinical trial updates for its lead asset, CONV01-α (225Ac-J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225 (225Ac). Data will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will take place February 13-15, 2025, in San Francisco, California. The first presentation, titled "Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer," reported clinical follow-up of a Phase I dose-escalation trial exploring the addition of CONV01-α to 177Lu-PSMA-I&T, a PSMA-targeted beta emitting small molecule for the treatment of advanced prostate cancer. The study population presented included 18 patients (six at each dose level of CONV01-α) with progressive metastatic castration-resistant prostate cancer (mCRPC). Relatively low doses of CONV01-α were used. Data showed that the median overall survival was 29.8 months, with 10 patients still alive at the time of submission. Five patients were free from PSA progression at one year including one patient progression-free at 34 months on no active therapy. A decline in prostate-specific antigen (PSA) levels was seen in 94% of patients, 64% of patients achieved a PSA50 and 28% achieved a PSA90 response. Additionally, circulating tumor cell count changes were seen, with 80% of evaluable patients converting from "unfavorable" to "favorable." High grade adverse events were rare. "The impressive clinical activity is consistent with our pre-clinical data demonstrating that the antibody/ligand combination delivers a synergistic dose to tumor. Importantly, the synergistic tumor dose is achieved in the absence of additive toxicity due to the non-overlapping normal organ biodistribution of the ligand and antibody. This was also confirmed by the benign safety profile in the trial. The dosimetry and safety profile suggest the potential for additional cycles beyond the two cycles used in this trial. That the overall survival in this trial was double that of the Phase III VISION trial of 177Lu PSMA-617 further increases our enthusiasm for future trials of this combination," said Neil Bander, MD, Convergent's Co-Founder and Chief Scientific Officer and Professor Emeritus of Urology at Weill Cornell Medicine. The second presentation, titled "CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of Ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer," is a "Trials in Progress" presentation of the three-part company sponsored Phase II trial evaluating the safety and efficacy of CONV01-α (225Ac-J591) monotherapy in patients with castration-resistant prostate cancer. Philip Kantoff, MD, Co-Founder and CEO said, "CONVERGE-01 is intended to confirm the high response rate and durability of CONV01-a monotherapy and solidify the path forward to our pivotal trial." About CONV01-α CONV01-α, Convergent's alpha-emitting radioantibody, combines the precision and pharmacokinetics of antibodies with the tumor-killing potential of alpha-emitting radionuclides. Specifically, CONV01-α uses a humanized monoclonal antibody targeted at prostate-specific membrane antigen (PSMA), which is highly overexpressed in prostate cancer cells. Since PSMA is a validated target, several therapeutics are directed at this antigen, and CONV01-α is differentiated by its use of both an antibody and alpha emitter. CONV01-α is linked to a powerful radionuclide called Ac-225, which releases alpha particles that kill cancer cells through DNA double-strand breaks. Unlike other radioactive sources, alpha particles deliver high-energy radiation over very short distances, thereby minimizing radiation exposure to healthy neighboring cells and tissues. Pairing highly selective antibodies with such a powerful, yet precise, payload offers the ideal combination to treat many types of cancers. Convergent Therapeutics is currently enrolling into the CONVERGE-01 Phase II monotherapy trial to confirm the high response rate, durability and safety of CONV01-a pre and post radioligand beta. About Convergent Therapeutics, Inc. Convergent Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-selective alpha radioantibodies to target cancer. The company was founded by world-renowned experts in clinical care and research, drug development, and cancer biology and its proprietary platform is licensed from Cornell University. In harnessing the selectivity of antibodies and tumor-destructive potential of alpha radioisotopes, Convergent's radioantibodies precisely target cancer cells with potent, localized radiation. For more information, please visit and follow us on X and LinkedIn. Media Relations: Bryan Blatstein Spectrum Science 917-714-2609 [email protected] SOURCE Convergent Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultASCOPhase 1Phase 2

21 Nov 2024

·www.globenewswire.com

Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors

SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf therapies that aim to realize the full reach and promise of CAR T-cells, today announced that Scott Myers has been appointed as Chairman of its Board of Directors, succeeding Dieter Weinand who will remain as an advisor. “As Umoja evolves to clinical stage with significant upcoming milestones, I look forward to working with Scott as our Board Chairman,” said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja. “Scott’s history as both a CEO and chairperson of multiple biotechnology companies in the Pacific Northwest, through significant periods of growth and clinical milestones, will be invaluable as Umoja looks to 2025 and beyond. I would also like to acknowledge and personally thank Dieter for his important contributions to Umoja’s progress over the past two years and am pleased that Dieter has agreed to stay on as strategic advisor for Scott and myself as we continue to build Umoja”. Scott Myers added, “Umoja is uniquely positioned as the leader for in vivo CAR-T cell therapies, with clinical trials recently initiating in multiple geographies and the industry’s first US IND. I am both humbled and excited at the significant opportunity in front of us: to truly transform the way CAR-T cell therapies are delivered so that they may reach their full potential impact on patients.” Mr. Myers currently chairs the boards of directors for Zentalis Pharmaceuticals, Convergent Therapeutics, and Dynavax Technologies. He previously chaired the boards of directors for Ironshore until its acquisition by Collegium Pharmaceuticals and Harpoon Therapeutics until its acquisition by Merck, both in 2024. He was also President and CEO of Viridian Therapeutics, AMAG Pharmaceuticals, Rainier Therapeutics, and Cascadian Therapeutics, and has held additional board and executive leadership roles at other biotechnology and pharmaceutical companies. Mr. Myers holds an MBA in finance from the University of Chicago’s Graduate School of Business (Booth) and a B.A. in Biology from Northwestern University. About Umoja Biopharma Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR-T cell therapies in both oncology and autoimmunity. Umoja’s VivoVec™ in vivo gene delivery technology empowers a patient’s own immune system to fight disease. Enabling its core technology is the Company’s state-of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. Umoja believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with Umoja on LinkedIn and visit http://umoja-biopharma.com/. Investors Grace KimHead of Investor Relationsgrace.kim@umoja-biopharma.com Media Matt Wright Real Chemistrymwright@realchemistry.com

Executive ChangeAcquisitionImmunotherapy

100 Deals associated with Convergent Therapeutics, Inc.

100 Translational Medicine associated with Convergent Therapeutics, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 01 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Actinium 225-J591 ( PSMA )	PSMA-Positive Castration-Resistant Prostatic Cancer More	Phase 2
In-111 rosopatamab tetraxetan ( PSMA )	PSMA-Positive Castration-Resistant Prostatic Cancer More	Phase 2

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis